Characteristics of Type 2 Diabetes Patients, Treated With Insulin and Their Follow up Care in Guadeloupe (DT2IT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03362762|
Recruitment Status : Completed
First Posted : December 5, 2017
Last Update Posted : December 5, 2017
Type 2 diabetes is a major problem of public health in the French West Indies, with an estimated prevalence of 8%, twice more than in France. In Guadeloupe, according to the statistical data of hospital morbidity in 2004, 2643 hospital stays were diagnosed with diabetes. These cases mainly concerned woman (62%) and the elderly, from 45 to 74 years old (67%).
The main objective of this research is to describe the insulin protocol used in Guadeloupe for treated type 2 diabetes patients and their characteristics:
- The duration of the type 2 diabetes
- Time elapsing between the diagnosis and the treatment by insulin
- Where the follow up care took place
- Existence of complications
Secondary objectives were to describe the link between the HbA1c rate and the insulin therapy protocol. And also to present the main inconveniences expressed by patients and their degree of autonomy.
|Condition or disease||Intervention/treatment|
|Type 2 Diabetes Treated With Insulin||Other: Description of plans insuliniques used in Guadeloupe in the type 2 diabetes and the characteristics of the handled patients:|
Nowadays the set up for insulin treatment is available in general practitioners' offices. However, it is restrained by the reticence of patients and physicians. For type 2 diabetes, insulin therapy is well managed and there is ongoing progress. But there are still some questions about the effect of the treatment in the everyday life of patients: culture, fear, material resources, necessity of education.
Ignorance and prejudices on insulin injection are still prevalent and often it delays for more than a year the time when patients have to switch an insulin treatment for unbalanced chronic disorder.
Type 2 diabetes patients think that the treatment is heavy, can lead to serious hypoglycemia, is uncomfortable for family and can cause fear.
Education of the patients can reduce ignorance and prejudices about insulin treatment.
Nowadays studies show that diabetes patients want to be more involved in the decisions linked to their treatment which impact their perception of the disease and the treatment.
Auto measurement of glycaemia can help the patient better manage his disease and make him understand the importance of controlling his glycaemia levels.
This study could allow to:
- Offer a new care organization for a better use of resources (network, patient therapeutic education…)
- Set up adequate training for professionals and for patients being cared for in medical offices.
- Improve the glycemic balance of patients and slower the growth of degenerative complications.
|Study Type :||Observational|
|Actual Enrollment :||205 participants|
|Official Title:||Characteristics of Type 2 Diabetes Patients, Treated With Insulin and Their Follow up Care in Guadeloupe|
|Actual Study Start Date :||December 16, 2013|
|Primary Completion Date :||September 27, 2016|
|Study Completion Date :||September 27, 2016|
Other: Description of plans insuliniques used in Guadeloupe in the type 2 diabetes and the characteristics of the handled patients:
- Characteristic of type 2 diabetes patients, treated with insulin in Guadeloupe [ Time Frame: Trough study completion, an average of 2 years ]
A descriptive analysis will be done on the population concerned by the study, for the socio demographic, clinical and therapeutic characteristics.
- the duration of the type 2 diabetes,
- time elapsing between the diagnostic and the treatment by insulin,
- place of the follow up care,
- existence of complications.
- Describe the relation between the rate of HbAC and the plan of insulinothérapie [ Time Frame: Trough study completion, an average of 2 years ]Sreening of HbAC
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03362762
|University Hospital Center of Pointe-à-Pitre|
|Pointe-à-Pitre, Guadeloupe, 97159|
|Principal Investigator:||Pauline NOUVIER KANGAMBEGA, medicine degree, diabetes||Hospital University Center of Pointe-à-Pitre|